Latest news

Search
Categories
News archive

Subscription for Shares in Nanologica´s Rights Issue

The subscription period for shares in Nanologica´s rights issue has now started. For information on how to subscribe, please see below links:   Swedish: https://nanologica.com/foretradesemission-2024/ English: https://nanologica.com/rights-issue-2024/   Subscription period: 28 Feb – 13 Mar 2024 Subscription price: SEK 6.75

Read more »

Nanologica offentliggör prospekt avseende företrädesemission

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SINGAPORE, SYDAFRIKA, ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDET, PUBLICERINGEN ELLER DISTRIBUTIONEN AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG, VARA FÖREMÅL FÖR LEGALA RESTRIKTIONER ELLER SKULLE KRÄVA REGISTRERING ELLER ANDRA ÅTGÄRDER. Nanologica AB (publ) (”Nanologica” eller ”Bolaget”) offentliggör prospekt med anledning av den företrädesemission av aktier motsvarande cirka 54,2 MSEK som beslutades av styrelsen den 30 januari

Read more »

Nanologica Delivers NLAB SIV™ to a Customer in Asia to a Value of over MSEK 4

Nanologica has made the first delivery of the company’s non-silica-based purification media NLAB Siv™ to a customer in Asia against an order received in November. The value amounts to over MSEK 4. NLAB Siv™ is a non-silica-based purification media that has been developed together with a customer who sells a number of pharmaceutical products. NLAB Siv™ is used for purification through preparative chromatography and the customer has expressed a desire to replace the purification media

Read more »

CEO Comment Q4 2023

CEO COMMENT During the last quarter of the year, Nanologica took clear steps forward. The production problems we have wrestled with during the year have now been handled and several deliveries to customers have been made. After rigorous testing of our silica-based purification media NLAB Saga®, we made a delivery in October to one of the world’s largest insulin manufacturers in Asia against an order we received in 2022. We have been determined to ensure

Read more »

Year-End Report 2023 Nanologica AB (publ)

FINANCIAL SUMMARY Net sales for the fourth quarter amounted to TSEK 75 (674) and for the full year to TSEK 1,443 (1,555) The operating loss for the quarter amounted to TSEK -35,638 (-13,251) and for the full year to TSEK -69,963 (-50,850). Operating loss was affected by write-downs of tangible and intangible assets during the quarter as well as for the full year totaling TSEK 14,523 (0) Loss after tax for the quarter amounted to

Read more »